Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Mining human antibody repertoires</title><author><name sortKey="Beerli, Roger R" sort="Beerli, Roger R" uniqKey="Beerli R" first="Roger R" last="Beerli">Roger R. Beerli</name><affiliation><nlm:aff id="A1">Cytos Biotechnology AG; Schlieren, Switzerland</nlm:aff></affiliation></author><author><name sortKey="Rader, Christoph" sort="Rader, Christoph" uniqKey="Rader C" first="Christoph" last="Rader">Christoph Rader</name><affiliation><nlm:aff id="A2">Experimental Transplantation and Immunology Branch; Center for Cancer Research; National Cancer Institute; National Institutes of Health; Bethesda, MD USA</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">20505349</idno><idno type="pmc">3180084</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180084</idno><idno type="RBID">PMC:3180084</idno><idno type="doi">10.4161/mabs.2.4.12187</idno><date when="2010">2010</date><idno type="wicri:Area/Pmc/Corpus">000A64</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000A64</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Mining human antibody repertoires</title><author><name sortKey="Beerli, Roger R" sort="Beerli, Roger R" uniqKey="Beerli R" first="Roger R" last="Beerli">Roger R. Beerli</name><affiliation><nlm:aff id="A1">Cytos Biotechnology AG; Schlieren, Switzerland</nlm:aff></affiliation></author><author><name sortKey="Rader, Christoph" sort="Rader, Christoph" uniqKey="Rader C" first="Christoph" last="Rader">Christoph Rader</name><affiliation><nlm:aff id="A2">Experimental Transplantation and Immunology Branch; Center for Cancer Research; National Cancer Institute; National Institutes of Health; Bethesda, MD USA</nlm:aff></affiliation></author></analytic><series><title level="j">mAbs</title><idno type="ISSN">1942-0862</idno><idno type="eISSN">1942-0870</idno><imprint><date when="2010">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Human monoclonal antibodies (mAbs) have become drugs of choice for the management of an increasing number of human diseases. Human antibody repertoires provide a rich source for human mAbs. Here we review the characteristics of natural and non-natural human antibody repertoires and their mining with non-combinatorial and combinatorial strategies. In particular, we discuss the selection of human mAbs from naïve, immune, transgenic and synthetic human antibody repertoires using methods based on hybridoma technology, clonal expansion of peripheral B cells, single-cell PCR, phage display, yeast display and mammalian cell display. Our reliance on different strategies is shifting as we gain experience and refine methods to the efficient generation of human mAbs with superior pharmacokinetic and pharmacodynamic properties.</p></div></front></TEI><pmc article-type="review-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">MAbs</journal-id><journal-id journal-id-type="publisher-id">mAbs</journal-id><journal-title-group><journal-title>mAbs</journal-title></journal-title-group><issn pub-type="ppub">1942-0862</issn><issn pub-type="epub">1942-0870</issn><publisher><publisher-name>Landes Bioscience</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">20505349</article-id><article-id pub-id-type="pmc">3180084</article-id><article-id pub-id-type="publisher-id">1942-0862-2-4-3</article-id><article-id pub-id-type="doi">10.4161/mabs.2.4.12187</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Mining human antibody repertoires</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Beerli</surname><given-names>Roger R</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="author-notes" rid="FN1">†</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Rader</surname><given-names>Christoph</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib></contrib-group><aff id="A1"><label>1</label>Cytos Biotechnology AG; Schlieren, Switzerland</aff><aff id="A2"><label>2</label>Experimental Transplantation and Immunology Branch; Center for Cancer Research; National Cancer Institute; National Institutes of Health; Bethesda, MD USA</aff><author-notes><fn fn-type="present-address" id="FN1"><label>†</label><p>Current Address: Intercell AG; Wagistrasse 25; CH-8952 Schlieren, Switzerland</p></fn><corresp>Correspondence to: Roger R. Beerli and Christoph Rader; Email: <email>rbeerli@intercell.com</email> and <email>raderc@mail.nih.gov</email></corresp></author-notes><pub-date pub-type="ppub"><season>Jul-Aug</season><year>2010</year></pub-date><pub-date pub-type="epub"><day>1</day><month>7</month><year>2011</year></pub-date><volume>2</volume><issue>4</issue><fpage>365</fpage><lpage>378</lpage><history><date date-type="received"><day>26</day><month>3</month><year>2010</year></date><date date-type="accepted"><day>27</day><month>4</month><year>2010</year></date></history><permissions><copyright-statement>Copyright © 2010 Landes Bioscience</copyright-statement><copyright-year>2010</copyright-year></permissions><abstract><p>Human monoclonal antibodies (mAbs) have become drugs of choice for the management of an increasing number of human diseases. Human antibody repertoires provide a rich source for human mAbs. Here we review the characteristics of natural and non-natural human antibody repertoires and their mining with non-combinatorial and combinatorial strategies. In particular, we discuss the selection of human mAbs from naïve, immune, transgenic and synthetic human antibody repertoires using methods based on hybridoma technology, clonal expansion of peripheral B cells, single-cell PCR, phage display, yeast display and mammalian cell display. Our reliance on different strategies is shifting as we gain experience and refine methods to the efficient generation of human mAbs with superior pharmacokinetic and pharmacodynamic properties.</p></abstract><kwd-group><title>Key words</title><kwd>human monoclonal antibodies</kwd><kwd>B cells</kwd><kwd>hybridoma technology</kwd><kwd>display technologies</kwd><kwd>antibody libraries</kwd><kwd>antibody engineering</kwd></kwd-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV2/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A64 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000A64 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV2
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.33. |  |